News AZ and Merck & Co ovarian cancer drug gets expanded US use FDA approves Lynparza's use in a wider group of women.
Views & Analysis AZ looks to pay-for-performance to bolster cardio-diabetes f... While many of the hopes and disappointments for AZ’s business are around oncology, it still needs its cardiovascular and diabetes portfolio to perform.
News Regeneron ends development of RSV antibody Regeneron dumps suptavumab after phase 3 trial failure.
News AZ immunotherapy gets FDA boost in early lung cancer Imfinzi given Breakthrough Therapy designation from the FDA.
News Soriot commits to AstraZeneca as shares slide AstraZeneca (AZ) has tried to put a brave face on today’s news that its immunotherapy combination is unlikely to be a contender in lung cancer.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
